Key result
Active smoking did not significantly affect ACT values or the incidence of arterial thrombo-embolic (5.7% vs 4.7%, p=0.55) and hemorrhagic complications (18% vs 15%, p=0.29) during NCAP.
Why the study?
Although smoking affects hemostasis, no literature was available regarding its effect on activated clotting time used to monitor heparin during noncardiac arterial procedures.
Does current smoking affect activated clotting time and the incidence of complications in patients undergoing noncardiac arterial procedures?
Cohort (n=773)
Yes
Does current smoking affect activated clotting time and the incidence of complications in patients undergoing noncardiac arterial procedures?
Smoking status does not significantly alter the activated clotting time response to heparin or the rate of perioperative complications in patients undergoing noncardiac arterial procedures.
Answers are grounded in this paper and cite their sources.
Smoking status need not guide heparin dosing in NCAP; leaves open other determinants of ACT response and complications.
PURPOSE: Smoking is a well-known risk factor for developing arterial diseases and for an increase of complications during and after vascular procedures. Although smoking has a proven effect on hemostasis, no literature is available on the effect of smoking on the activated clotting time (ACT), which is used to monitor the effect of heparin during noncardiac arterial procedures (NCAP). The aim of this study was to examine the effect of smoking on ACT values and the incidence of complications during the same admission or 30 day follow-up of NCAP. MATERIALS AND METHODS: A post hoc analysis of a prospective multicenter cohort study was performed. Patients older than 18 years, who underwent NCAP between December 2016 and April 2021, were enrolled. Patients were divided into 2 groups based on smoking status: never/former smokers and current smokers. Two heparin dosing protocols were used: an initial bolus of 5000 IU or 100 IU/kg bodyweight. RESULTS: In total, 773 patients met the inclusion criteria. Five minutes after administration of 5000 IU of heparin, mean ACT values were 190 and 196 seconds for nonsmokers and smokers, respectively (p=0.078). After 100 IU/kg of heparin, mean ACT values were 229 and 226 seconds for nonsmokers and smokers, respectively (p=0.37). Incidence of complications in the whole study cohort was not significantly different for nonsmokers compared with smokers (arterial thrombo-embolic complication [ATEC] 4.7% vs 5.7% p=0.55; hemorrhagic complications 15% vs 18% p=0.29). In subgroup-analysis, a significant difference between smoking groups was found for hemorrhagic complications after open aneurysm repair (p=0.024). However, after adjusting for confounders, the difference between the smoking groups annulled. CONCLUSION: The results of this study suggest that smoking does not have a significant effect on ACT values or on the incidence of complications in NCAP. Large-scale studies are required to further analyze potential factors having an effect on the ACT and perioperative and postoperative complications, which could help individualize heparinization strategy.Clinical impactThere is high variance between patients in their response on administration of heparin, this is not yet fully understood. This study investigated the effect of smoking in a large prospective multicentre cohort. The results suggests that active smoking does not have an effect on the activated clotting time after administration of heparin. Also no significant effect of smoking could be found on the incidence of all registered complications. Monitoring of the effect of heparin remains important to provide patients with safe anticoagulation during vascular procedures.
No takes yet. Share an insight, caveat, or question.
Roosendaal et al. (2023) conducted a cohort in Noncardiac arterial procedures (n=773). Current smoking vs. Never/former smokers was evaluated on Arterial thrombo-embolic complications (p=0.55). Active smoking did not significantly affect ACT values or the incidence of arterial thrombo-embolic (5.7% vs 4.7%, p=0.55) and hemorrhagic complications (18% vs 15%, p=0.29) during NCAP.
Synapse has enriched 10 related papers. Consider them for comparative context: